- Home
- GEVO vs RIGL Comparison
GEVO vs RIGL Comparison
Compare GEVO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- RIGL
- Stock Information
- Founded
- GEVO 2005
- RIGL 1996
- Country
- GEVO United States
- RIGL United States
- Employees
- GEVO N/A
- RIGL N/A
- Industry
- GEVO Major Chemicals
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- RIGL Health Care
- Exchange
- GEVO Nasdaq
- RIGL Nasdaq
- Market Cap
- GEVO 418.4M
- RIGL 335.5M
- IPO Year
- GEVO 2011
- RIGL 2000
- Fundamental
- Price
- GEVO $1.73
- RIGL $38.85
- Analyst Decision
- GEVO Buy
- RIGL Buy
- Analyst Count
- GEVO 2
- RIGL 5
- Target Price
- GEVO $7.58
- RIGL $38.20
- AVG Volume (30 Days)
- GEVO 9.4M
- RIGL 995.6K
- Earning Date
- GEVO 08-11-2025
- RIGL 08-05-2025
- Dividend Yield
- GEVO N/A
- RIGL N/A
- EPS Growth
- GEVO N/A
- RIGL N/A
- EPS
- GEVO N/A
- RIGL 5.43
- Revenue
- GEVO $80,187,000.00
- RIGL $267,921,000.00
- Revenue This Year
- GEVO $909.99
- RIGL $59.93
- Revenue Next Year
- GEVO $22.37
- RIGL N/A
- P/E Ratio
- GEVO N/A
- RIGL $7.15
- Revenue Growth
- GEVO 341.75
- RIGL 105.62
- 52 Week Low
- GEVO $0.67
- RIGL $12.66
- 52 Week High
- GEVO $3.39
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- GEVO 57.77
- RIGL 68.57
- Support Level
- GEVO $1.54
- RIGL $39.00
- Resistance Level
- GEVO $1.86
- RIGL $42.08
- Average True Range (ATR)
- GEVO 0.14
- RIGL 2.32
- MACD
- GEVO 0.01
- RIGL -0.37
- Stochastic Oscillator
- GEVO 31.15
- RIGL 53.26
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. The operating segments are the Gevo segment, GevoFuels segment, and the GevoRNG segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure. The company derives maximum revenue from the GevoRNG segment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.